NHIA seeks permanent payment for COVID therapy
By HME News Staff
Updated 9:12 AM CDT, Thu May 26, 2022
ALEXANDRIA, Va. – The National Home Infusion Association has sent a letter to Xavier Becerra, secretary of the U.S. Department of Health and Human Service, asking the agency to make permanent Medicare payment for COVID-19 monoclonal antibodies (mABs). HHS’s vaccine program created coverage for home and suite-based infusions of COVID mABs, but it's set to expire when the public health emergency ends. NHIA points out that access to home infusion for mABs for the treatment and prevention of hospitalization and death due to severe COVID-19 is critical to maintaining preparedness for potential future variants. With no oral therapies approved for prophylaxis, mABs are the only source of preventive therapy for vulnerable patients who do not respond to vaccines, such as transplant patients, cancer patients and the immunocompromised.
Comments